Business context and reporting period
Trxade Group, Inc. (the registrant named in the filing) reported unaudited results for the three months ended March 31, 2018, compared with the three months ended March 31, 2017. Its core business is a web-based marketplace connecting independent pharmacies with pharmaceutical suppliers; it reported more than 8,500 registered pharmacy members. The filing describes Integra Pharma Solutions as having limited operations and no revenue, and Alliance Pharma Solutions as having no operations or revenue.
The request metadata names Scienture Holdings, Inc., but the supplied filing is for Trxade Group, Inc.; verify that this is the intended filing.
Financial performance and position
- Revenue: $852,923, up 14.3% from $745,943. Management attributed the increase to higher platform transaction-fee income and customer additions.
- Expenses and profit: Operating expenses were $754,195, versus $604,493; operating income was $98,728, down 30.2% from $141,450. Net income was $82,269, up 3.2% from $79,726. Net income per basic and diluted share was reported as $0.00 in both periods.
- Margins: Operating margin was approximately 11.6%, compared with 19.0%; net margin was approximately 9.6%, compared with 10.7%. The filing does not present gross profit or a gross margin.
- Cash flow: Operating activities provided $66,663, compared with $48,283 used in the prior-year quarter. Financing activities used $60,739, primarily for debt repayments. Cash increased $5,924 to $189,838.
- Liquidity: Current assets were $670,911 and current liabilities were $469,067, giving working capital of $201,844, versus $82,119 at December 31, 2017. Cash was $189,838 at quarter-end.
- Debt and liabilities: Total liabilities were $873,119, exceeding total assets of $680,911; shareholders’ deficit was $192,208. Short-term related-party convertible debt was $201,725, and long-term convertible and related-party notes totaled $404,052. The $10,739 short-term promissory note was repaid during the quarter.
Material changes and management commentary
- General and administrative expense excluding stock-based compensation was $716,739, compared with $524,856 in the prior-year quarter; management cited higher employee cash compensation. The financial statements report total general and administrative expense of $754,195, including $37,456 of options expense.
- In January 2018, annual salaries for two executives were amended from $165,000 and $125,000 to $200,000 and $150,000, respectively.
- Management identified continued platform development, customer growth, and increased operating revenue as priorities. It estimated approximately $2.425 million in operating expenses and working-capital requirements for the next 12 months and said it expects to pursue additional financing. It cautioned that financing may not be available on favorable terms, or at all, and that future operations may not generate significant positive cash flow.
- Topic 606 was adopted January 1, 2018, with no material financial-statement impact. No off-balance-sheet arrangements or legal proceedings were reported; the company said risk factors were unchanged from its 2017 Form 10-K.
- Management concluded disclosure controls and procedures were not effective at quarter-end. It reported no material change in internal control over financial reporting during the quarter.
Investor verification points
- Confirm the filing’s issuer: the supplied 10-Q identifies Trxade Group, Inc., not Scienture Holdings, Inc.
- Assess the company’s ability to fund its stated $2.425 million next-12-month requirements, given quarter-end cash of $189,838 and management’s stated need for additional capital.
- Review the terms, maturity dates, and repayment or refinancing prospects for related-party debt, including the $201,725 short-term convertible balance.
- Reconcile the MD&A expense presentation with the financial statements, particularly general and administrative expense and stock-based compensation.
- Consider the disclosed ineffective disclosure controls and the implications of executive compensation increases and related-party financing.